Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathryn S Ivy

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Current Hematologic Malignancy Reports|June 24, 2018
Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic SyndromesKathryn S Ivy, P Brent Ferrell
Mededpublish (2016)|February 26, 2024
Incorporating engaged learning into medical student large group sessionsKathryn S Ivy, Allison R Larson
Oncotarget|December 18, 2015
Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcomaParag P Patwardhan, Kathryn S Ivy, Elgilda Musi, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Current Hematologic Malignancy Reports|June 24, 2018
Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic SyndromesKathryn S Ivy, P Brent Ferrell
Mededpublish (2016)|February 26, 2024
Incorporating engaged learning into medical student large group sessionsKathryn S Ivy, Allison R Larson
Oncotarget|December 18, 2015
Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcomaParag P Patwardhan, Kathryn S Ivy, Elgilda Musi, et al.
Pageof 1